News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Maxygen, Inc. Says Drug Under Amgen Patent Cloud
June 13, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BANGALORE, June 13 (Reuters) - Shares of biotechnology firm Maxygen Inc slid as much as 30 percent after news that it could face a legal patent battle with sector leader Amgen Inc over its lead cancer drug.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Amgen
MORE ON THIS TOPIC
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
December 4, 2025
·
2 min read
·
Tristan Manalac
Policy
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026
December 3, 2025
·
4 min read
·
Jennifer Smith-Parker
Drug Development
CRO Boom in APAC Region, With China at the Forefront
November 19, 2025
·
5 min read
·
Jennifer Smith-Parker
FDA
Makary Eyes ‘America-First’ User Fee Structure as Renewal Negotiations Approach
November 19, 2025
·
2 min read
·
Tristan Manalac
